NO920703L - Fusjonsproteiner som omfatter gm-csf og il-3 - Google Patents

Fusjonsproteiner som omfatter gm-csf og il-3

Info

Publication number
NO920703L
NO920703L NO92920703A NO920703A NO920703L NO 920703 L NO920703 L NO 920703L NO 92920703 A NO92920703 A NO 92920703A NO 920703 A NO920703 A NO 920703A NO 920703 L NO920703 L NO 920703L
Authority
NO
Norway
Prior art keywords
csf
fusion proteins
proteins including
fusion
alone
Prior art date
Application number
NO92920703A
Other languages
English (en)
Other versions
NO920703D0 (no
NO301888B1 (no
Inventor
Benson M Curtis
Linda S Park
David J Cosman
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO920703D0 publication Critical patent/NO920703D0/no
Publication of NO920703L publication Critical patent/NO920703L/no
Publication of NO301888B1 publication Critical patent/NO301888B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO920703A 1989-08-22 1992-02-21 Fremgangsmåte for fremstilling av fusjonsproteiner som omfatter GM-CSF og IL-3, DNA-sekvens som koder for slike og rekombinant ekspresjonsvektor som omfatter en slik DNA-sekvens NO301888B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39714689A 1989-08-22 1989-08-22
PCT/US1990/004599 WO1991002754A1 (en) 1989-08-22 1990-08-14 Fusion proteins comprising gm-csf and il-3

Publications (3)

Publication Number Publication Date
NO920703D0 NO920703D0 (no) 1992-02-21
NO920703L true NO920703L (no) 1992-04-14
NO301888B1 NO301888B1 (no) 1997-12-22

Family

ID=23570012

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920703A NO301888B1 (no) 1989-08-22 1992-02-21 Fremgangsmåte for fremstilling av fusjonsproteiner som omfatter GM-CSF og IL-3, DNA-sekvens som koder for slike og rekombinant ekspresjonsvektor som omfatter en slik DNA-sekvens

Country Status (11)

Country Link
EP (1) EP0489116B1 (no)
JP (1) JP3115318B2 (no)
AT (1) ATE103932T1 (no)
AU (1) AU632372B2 (no)
DD (1) DD297188A5 (no)
DE (1) DE69007975T2 (no)
DK (1) DK0489116T3 (no)
ES (1) ES2055445T3 (no)
FI (1) FI920764A7 (no)
NO (1) NO301888B1 (no)
WO (1) WO1991002754A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0546124T4 (da) * 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
JPH05502463A (ja) * 1990-09-28 1993-04-28 オーソ・フアーマシユーチカル・コーポレーシヨン ハイブリツド成長因子
AU664030B2 (en) * 1991-02-27 1995-11-02 Micromet Ag Serine-rich peptide linkers
DE69231467T2 (de) 1991-05-10 2001-01-25 Genentech, Inc. Auswählen von agonisten und antagonisten von liganden
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
ATE173763T1 (de) * 1991-08-30 1998-12-15 Hutchinson Fred Cancer Res Hybride cytokine
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US7091319B1 (en) 1992-11-24 2006-08-15 Bauer S Christopher IL-3 variant hematopoiesis fusion protein
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
JPH08503706A (ja) * 1992-11-24 1996-04-23 ジー．ディー．サール アンド カンパニー インターロイキン−３（ｉｌ−３）多重変異ポリペプチド
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6361977B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
AU686840B2 (en) * 1994-07-07 1998-02-12 Immunex Corporation Fusion proteins comprising GM-CSF and antigens and their expression in yeast
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
KR20130032866A (ko) * 2010-02-18 2013-04-02 더 유니버시티 오브 멜버른 만성 염증 상태의 치료
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
MX375441B (es) 2013-07-18 2025-03-06 Vib Vzw Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
US9732135B2 (en) 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
DK3022226T3 (en) 2013-07-19 2019-03-25 Vib Vzw TARGETED MODIFIED IL-1 FAMILY MEMBERS
AU2014291961B2 (en) 2013-07-19 2018-09-27 Centre Hospitalier Regional Universitaire De Montpellier Targeted modified TNF family members
JP6067540B2 (ja) * 2013-11-07 2017-01-25 日本曹達株式会社 防蟻性能試験用器具
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
WO2019032661A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0167548B1 (en) * 1983-12-23 1993-02-10 The Australian National University Cloning of cdna and expression of murine-interleukin-3
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
EP0276846A3 (en) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Colony-stimulating factor derivatives
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
AU632372B2 (en) 1992-12-24
JP3115318B2 (ja) 2000-12-04
FI920764A0 (fi) 1992-02-21
NO920703D0 (no) 1992-02-21
DK0489116T3 (da) 1994-05-02
EP0489116B1 (en) 1994-04-06
FI920764A7 (fi) 1992-02-21
ATE103932T1 (de) 1994-04-15
DD297188A5 (de) 1992-01-02
WO1991002754A1 (en) 1991-03-07
NO301888B1 (no) 1997-12-22
AU6424090A (en) 1991-04-03
JPH05500806A (ja) 1993-02-18
DE69007975T2 (de) 1994-07-21
ES2055445T3 (es) 1994-08-16
DE69007975D1 (de) 1994-05-11
EP0489116A1 (en) 1992-06-10

Similar Documents

Publication Publication Date Title
NO920703D0 (no) Fusjonsproteiner som omfatter gm-csf og il-3
MX9203426A (es) Proteinas de fusion que comprenden gm-csf e il-3.
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
IS5887A (is) Interferón-beta bræðsluprótín og notkun þeirra
FI20002013L (fi) HCV-fuusioproteiini
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
CA2122724A1 (en) Fusion Proteins Comprising MGF and IL-3
NO992779L (no) OB-fusjonsproteinpreparater og fremgangsmåte
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
BR9407583A (pt) Processos para produzir uma proteina bcl-2 mutante para identificar agentes modulantes de bcl-2 candidatos um bcl-2 mutante e proteinas bcl-2 mutantes e para inibir a atividade repressora de morte de células de bcl-2 e polipeptideo bcl-2 mutante
DK19991D0 (da) Proteinpraeparationer
DK0538300T3 (da) O-Glycosyleret IFN-alfa
DK110190D0 (da) Alveolaere surfaktantproteiner
EP0483247A4 (en) Recombinantly produced human membrane cofactor protein (mcp)
FI954657A0 (fi) Biologisesti aktiivisia polypeptidifuusiodimeereja
NO924165D0 (no) Proteasedefisiente bakterieverter
NO891926D0 (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
FI942467A0 (fi) Proteesivakaat proteiinit
MY114223A (en) Fusion proteins comprising gm-csf and il-3
DE59008693D1 (de) Gewebs-Plasminogen-Aktivator-Derivat.
DK180290D0 (da) Monoxidil-gel og fremgangsmaade til fremstilling deraf
NO903967L (no) Dihydrocaffeinsyrederivater og farmasoeytiske preparater som inneholder disse.
ITRM920517A0 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
IT9047978A0 (it) Derivato biamminato della proteina sv-iv e procedimento per la sua preparazione.
DK718688A (da) 2-oxo-1-((substitueret sulfonyl)-amino)-carbonyl)azetidiner